Roche expands distribution alliance with the life science business of Merck KGaA, Darmstadt, Germany to include Kapa Biosystems qPCR and endpoint PCR Portfolios
Pleasanton, CA, November, 28, 2016 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced an expansion of their distribution alliance with the life science business of Merck KGaA, Darmstadt, Germany, to now include the qPCR and endpoint PCR portfolios1 from Kapa Biosystems. Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the US and Canada. Kapa Biosystems was previously acquired by Roche in December of 2015.
Increased customer access to Kapa NGS, HiFi kits through Roche Diagnostics Canada
KAPA HyperPlus library construction kits deliver rapid and robust results in high-throughput NGS pipeline
Roche finalizes acquisition of Kapa Biosystems to strengthen next-generation sequencing product offerings
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced regulatory clearance to finalize acquisition of Kapa Biosystems, Inc. (Kapa), a privately-held company headquartered in Wilmington, Massachusetts, US. Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications¹.
Kapa Biosystems today announced that it has earned ISO 13485:2003 certification for the design, development, and manufacturing of molecular biology kits and reagents for in vitro diagnostic applications. This certification is recognized as the international quality standard for medical devices.
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has signed a definitive agreement to acquire Kapa Biosystems, Inc. (Kapa) a privately-held company headquartered in Wilmington, Massachusetts, US. Kapa Biosystems is a provider of genomic tools in the life sciences sector that employs proprietary technologies to optimize enzymes for next-generation sequencing (NGS), as well as polymerase chain reaction (PCR) and real-time PCR applications¹.
10X Genomics and Kapa Biosystems today announced that Kapa’s DNA library preparation reagents have been incorporated into the GemCode Platform, enabling a more streamlined workflow generating high quality sequencing data.
Ribodepletion kit boosts NGS throughput and data quality for more comprehensive view of transcriptome
Kapa Biosystems Launches Inhibitor-Resistant qPCR Reagent Kit to Accelerate Workflows and Improve Target Amplification and Quantification of Crude Samples
KAPA PROBE FORCE qPCR Kit enables direct amplification of challenging samples for genotyping and gene expression applications in clinical research and agricultural testing applications
KAPA HyperPlus Kit features integrated DNA fragmentation and 2.5-hour library construction workflow and KAPA Stranded RNA-Seq Kit with RiboErase, the only solution able to remove up to 99.98% of rRNA for comprehensive transcriptome profiling
Kapa Biosystems Expands Partnership with Roche NimbleGen to Include RNA Sample Preparation for Targeted Next-Gen Sequencing
Customized version of KAPA Stranded RNA-Seq Kit enhances Roche NimbleGen SeqCap RNA product offering
Kapa Biosystems Strengthens European Commercial Operations with Dedicated Service and Support for Customers in the United Kingdom
Company increases regional investment to support continued success, accelerate future growth, and enhance overall customer experience
Dartmouth-Hitchcock Selects Kapa Biosystems Reagents to Assess Quantity and Quality of FFPE DNA for Translational Cancer Research Applications
Researchers to present data showcasing KAPA hgDNA Quantification and QC Kit’s ability to accurately predict next-gen sequencing performance, inform sample processing, and minimize unnecessary costs during AMP 2014 Annual Meeting.
A team of researchers from Stanford University found the combination of the KAPA Library Preparation Kits and the Roche NimbleGen sequence capture products to be an economical and ultrasensitive method for quantifying and enriching circulating tumor DNA (ctDNA).
Latest exclusive distribution agreement with Nippon Genetics builds on continued commercial success of Kapa’s genomics product portfolio over the past seven years in the Japanese market.
New exome sequencing offerings for neonatal, pediatric and adult-onset diagnosis feature faster turnaround times, reduced pricing and more comprehensive coverage
Kapa Biosystems, Inc., a leading supplier of reagents for the life science market, today announced that its KAPA Library Preparation Kits have been selected for use in the 100K Foodborne Pathogen Genome Project, an innovative collaboration between the U.S. Food and Drug Administration (FDA), the University of California, Davis, Agilent Technologies Inc., and the Centers for Disease Control and Prevention (CDC).
Kapa Biosystems, Inc., a leading supplier of reagents for the life science market, today announced the launch of products that improve performance and workflows for genomic research. The new suite of products enables researchers to apply the latest next-generation sequencing (NGS) technologies more effectively to millions of low quality and challenging samples, such as formalin-fixed paraffin-embedded (FFPE) tissue common in cancer profiling.
Company makes key management hires and relocates corporate and international headquarters to larger locations in Wilmington, Mass. and Cape Town, South Africa.
Roche and Kapa Biosystems announced today a partnership to provide an optimized NGS target enrichment workflow solution.